TNGX

21.7304.32%
AA

Alan Ashworth

Founder & Member of Scientific Advisory Board

Prof. Dr. Alan Ashworth, PhD, FRS, serves as President of UCSF Helen Diller Family Comprehensive Cancer Center, which he joined on March 01, 2014. He is also a Professor of Medicine in the Division of Hematology & Oncology at UCSF and Senior Vice President for Cancer Services with UCSF Health. He also served as Director of the center from March 01, 2014. He serves as Advisor of Overwater Ventures LLC since May 2026 and as Chairman of the Scientific Advisory Board of Leapfrog Bio, Inc. since March 2026. He serves as Independent Director of CytomX Therapeutics, Inc. since September 29, 2021. He is Founder of Tango Therapeutics, Inc. and also serves as Member of its Scientific Advisory Board since 2021. He serves as Member of the Advisory Board of Phoenix Molecular Designs Ltd since February 4, 2021 and as Member of the Scientific Advisory Board of Circle Pharma, Inc. since October 2020. Prof. Ashworth serves as Venture Partner of Catalio Capital Management, LP, Advisor of ProLynx Inc., and is Scientific Founder of Azkarra Therapeutics, Inc. and Co-Founder of Ovibio. He serves as a Member of the Scientific Advisory Board at Horizon Discovery Group Limited, London Genetics Ltd, Horizon Discovery Limited, Susan G. Komen for the Cure, Ambagon Therapeutics, Inc., Earli Inc., Cura Therapeutics, LLC, ClearNote Health, Inc., GLAdiator, PhoenixMD, Cambridge Science Corporation, and Bluestar Genomics Inc. He also serves as a Member of the International Scientific Advisory Board of The Netherlands Cancer Institute. Prof. Ashworth served as Member of the Scientific Resource Board of Genentech, Inc. until August 2023. He also served as the Chief Executive Officer of the Institute of Cancer Research and as the Director of the Breakthrough Breast Cancer Center. Prof. Ashworth has a Ph.D. in Biochemistry from University College London and a B.S. in Biochemistry & Chemistry from Imperial College.

Positions